Danaher Co. (NYSE:DHR) Receives $287.16 Consensus Target Price from Brokerages

Danaher Co. (NYSE:DHR) has received an average rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $287.16.

DHR has been the topic of a number of recent research reports. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Thursday. Royal Bank of Canada cut their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. TD Cowen upped their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC bought a new position in Danaher in the second quarter worth approximately $25,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the third quarter worth approximately $40,000. Finally, FSA Wealth Management LLC bought a new position in Danaher in the third quarter worth approximately $50,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $230.12 on Wednesday. The stock has a market capitalization of $166.21 billion, a P/E ratio of 43.91, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher has a 1 year low of $215.68 and a 1 year high of $281.70. The company’s 50-day moving average is $251.66 and its 200 day moving average is $258.69.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.02 earnings per share. On average, sell-side analysts expect that Danaher will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.